Significance of postoperative follow-up of patients with
metastatic colorectal cancer using circulating tumor DNA

J 2019

Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA

BENESOVA, Lucie, Tereza HALKOVA, Renata PTACKOVA, Anastasiya SEMYAKINA, Katerina MENCLOVA et. al.

Základní údaje

Originální název

Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA

Autoři

BENESOVA, Lucie (203 Česká republika, garant), Tereza HALKOVA (203 Česká republika), Renata PTACKOVA (203 Česká republika), Anastasiya SEMYAKINA (203 Česká republika), Katerina MENCLOVA (203 Česká republika), Jiri PUDIL (203 Česká republika), Miroslav RYSKA (203 Česká republika), Miroslav LEVY (203 Česká republika), Jaromir SIMSA (203 Česká republika), Filip PAZDIREK (203 Česká republika), Jiri HOCH (203 Česká republika), Milan BLAHA (203 Česká republika, domácí) a Marek MINARIK (203 Česká republika)

Vydání

World Journal of Gastroenterology, Baishideng, 2019, 1007-9327

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30219 Gastroenterology and hepatology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.665

Kód RIV

RIV/00216224:14110/19:00108601

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3748/wjg.v25.i48.6939

UT WoS

000511328600007

Klíčová slova anglicky

Circulating tumor DNA; Metastatic colorectal cancer; Postoperative; Radicality of resection; Follow-up; Recurrence

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 2. 2020 10:37, Mgr. Tereza Miškechová

Anotace

V originále

BACKGROUND One of the most notable applications for circulating tumor DNA (ctDNA) detection in peripheral blood of patients with metastatic colorectal cancer (mCRC) is a long-term postoperative follow-up. Sometimes referred to as a "liquid (re)biopsy" it is a minimally invasive procedure and can be performed repeatedly at relatively short intervals (months or even weeks). The presence of the disease and the actual extent of the tumor burden (tumor mass) within the patient's body can be monitored. This is of particular importance, especially when evaluating radicality of surgical treatment as well as for early detection of disease progression or recurrence. AIM To confirm the radicality of surgery using ctDNA and compare available methods for detection of recurrence in metastatic colorectal cancer. METHODS A total of 47 patients with detected ctDNA and indications for resection of mCRC were enrolled in the multicenter study involving three surgical centers. Standard postoperative follow-ups using imaging techniques and the determination of tumor markers were supplemented by ctDNA sampling. In addition to the baseline ctDNA testing prior to surgery, a postoperative observation was conducted by evaluating ctDNA presence up to a week after surgery and subsequently at approximately three-month intervals. The presence of ctDNA was correlated with radicality of surgical treatment and the actual clinical status of the patient. RESULTS Among the monitored patients, the R0 (curative) resection correlated with postoperative ctDNA negativity in 26 out of 28 cases of surgical procedures (26/28, 93%). In the remaining cases of R0 surgeries that displayed ctDNA, both patients were diagnosed with a recurrence of the disease after 6 months. In 7 patients who underwent an R1 resection, 4 ctDNA positivities (4/7, 57%) were detected after surgery and associated with the confirmation of early disease recurrence (after 3 to 7 months). All 15 patients (15/15, 100%) undergoing R2 resection remained constantly ctDNA positive during the entire follow-up period. In 22 cases of recurrence, ctDNA positivity was detected 22 times (22/22, 100%) compared to 16 positives (16/22, 73%) by imaging methods and 15 cases (15/22, 68%) of elevated tumor markers. CONCLUSION ctDNA detection in patients with mCRC is a viable tool for early detection of disease recurrence as well as for confirmation of the radicality of surgical treatment.

Návaznosti

NV15-27939A, projekt VaV

Název: Přínos nové technologie „liquid biopsy“ pro monitoraci komplexní léčby kolorektálního karcinomu ve 3.- 4. stádiu onemocnění

Citovat

BENESOVA, Lucie, Tereza HALKOVA, Renata PTACKOVA, Anastasiya SEMYAKINA, Katerina MENCLOVA, Jiri PUDIL, Miroslav RYSKA, Miroslav LEVY, Jaromir SIMSA, Filip PAZDIREK, Jiri HOCH, Milan BLAHA a Marek MINARIK. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA. World Journal of Gastroenterology. Baishideng, 2019, roč. 25, č. 48, s. 6939-6948. ISSN 1007-9327. Dostupné z: https://dx.doi.org/10.3748/wjg.v25.i48.6939.

@article{1624736,
   author = {Benesova, Lucie and Halkova, Tereza and Ptackova, Renata and Semyakina, Anastasiya and Menclova, Katerina and Pudil, Jiri and Ryska, Miroslav and Levy, Miroslav and Simsa, Jaromir and Pazdirek, Filip and Hoch, Jiri and Blaha, Milan and Minarik, Marek},
   article_number = {48},
   doi = {http://dx.doi.org/10.3748/wjg.v25.i48.6939},
   keywords = {Circulating tumor DNA; Metastatic colorectal cancer; Postoperative; Radicality of resection; Follow-up; Recurrence},
   language = {eng},
   issn = {1007-9327},
   journal = {World Journal of Gastroenterology},
   title = {Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA},
   url = {http://dx.doi.org/10.3748/wjg.v25.i48.6939},
   volume = {25},
   year = {2019}
}

TY  - JOUR
ID  - 1624736
AU  - Benesova, Lucie - Halkova, Tereza - Ptackova, Renata - Semyakina, Anastasiya - Menclova, Katerina - Pudil, Jiri - Ryska, Miroslav - Levy, Miroslav - Simsa, Jaromir - Pazdirek, Filip - Hoch, Jiri - Blaha, Milan - Minarik, Marek
PY  - 2019
TI  - Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA
JF  - World Journal of Gastroenterology
VL  - 25
IS  - 48
SP  - 6939-6948
EP  - 6939-6948
PB  - Baishideng
SN  - 10079327
KW  - Circulating tumor DNA
KW  - Metastatic colorectal cancer
KW  - Postoperative
KW  - Radicality of resection
KW  - Follow-up
KW  - Recurrence
UR  - http://dx.doi.org/10.3748/wjg.v25.i48.6939
L2  - http://dx.doi.org/10.3748/wjg.v25.i48.6939
N2  - BACKGROUND One of the most notable applications for circulating tumor DNA (ctDNA) detection in peripheral blood of patients with metastatic colorectal cancer (mCRC) is a long-term postoperative follow-up. Sometimes referred to as a "liquid (re)biopsy" it is a minimally invasive procedure and can be performed repeatedly at relatively short intervals (months or even weeks). The presence of the disease and the actual extent of the tumor burden (tumor mass) within the patient's body can be monitored. This is of particular importance, especially when evaluating radicality of surgical treatment as well as for early detection of disease progression or recurrence. AIM To confirm the radicality of surgery using ctDNA and compare available methods for detection of recurrence in metastatic colorectal cancer. METHODS A total of 47 patients with detected ctDNA and indications for resection of mCRC were enrolled in the multicenter study involving three surgical centers. Standard postoperative follow-ups using imaging techniques and the determination of tumor markers were supplemented by ctDNA sampling. In addition to the baseline ctDNA testing prior to surgery, a postoperative observation was conducted by evaluating ctDNA presence up to a week after surgery and subsequently at approximately three-month intervals. The presence of ctDNA was correlated with radicality of surgical treatment and the actual clinical status of the patient. RESULTS Among the monitored patients, the R0 (curative) resection correlated with postoperative ctDNA negativity in 26 out of 28 cases of surgical procedures (26/28, 93%). In the remaining cases of R0 surgeries that displayed ctDNA, both patients were diagnosed with a recurrence of the disease after 6 months. In 7 patients who underwent an R1 resection, 4 ctDNA positivities (4/7, 57%) were detected after surgery and associated with the confirmation of early disease recurrence (after 3 to 7 months). All 15 patients (15/15, 100%) undergoing R2 resection remained constantly ctDNA positive during the entire follow-up period. In 22 cases of recurrence, ctDNA positivity was detected 22 times (22/22, 100%) compared to 16 positives (16/22, 73%) by imaging methods and 15 cases (15/22, 68%) of elevated tumor markers. CONCLUSION ctDNA detection in patients with mCRC is a viable tool for early detection of disease recurrence as well as for confirmation of the radicality of surgical treatment.
ER  -

BENESOVA, Lucie, Tereza HALKOVA, Renata PTACKOVA, Anastasiya SEMYAKINA, Katerina MENCLOVA, Jiri PUDIL, Miroslav RYSKA, Miroslav LEVY, Jaromir SIMSA, Filip PAZDIREK, Jiri HOCH, Milan BLAHA a Marek MINARIK. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA. \textit{World Journal of Gastroenterology}. Baishideng, 2019, roč.~25, č.~48, s.~6939-6948. ISSN~1007-9327. Dostupné z: https://dx.doi.org/10.3748/wjg.v25.i48.6939.

Podrobný výpis o publikaci